Saturday 17 October 2026
Export HOWL’s income statement to Excel — free account
Werewolf Therapeutics, Inc.
HOWL Healthcare Biotechnology
Werewolf Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.9 million, down 90.5% from fiscal 2023. In the quarter to June 2026, revenue grew 256.1%, EPS grew 120.0% and free cash flow grew 146.5%, each against the same quarter a year earlier.
0.98
0.02
−2.00%
Follow HOWL
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(122.43%) | (123.88%) | (161.89%) | (119.86%) | |
| (66.32%) | (61.96%) | (68.09%) | (59.31%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(130.87%) | (224.22%) | (387.90%) | (212.45%) | |
Average Days of Receivables |
— | — | — | 0.00 | |
Free Cash Flow per Share |
(1.39) | (1.31) | (1.07) | (0.61) | |
Free Cash Flow |
(63.52) | (60.29) | (51.94) | (29.87) | |
Capital Expenditures |
— | — | — | 0.27 | |
| Other line items | |||||
Cash ROIC |
(54.30%) | (73.66%) | (88.56%) | (78.05%) | |
Accounts Receivable Turnover |
— | — | — | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 134.95% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 79.34% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 15.56% | |
Interest Coverage |
(13.85) | (11.50) | (10.40) | (6.87) | |
Operating CF/Net income |
0.87 | 0.99 | 0.92 | 0.87 | |
Depreciation/Fixed assets |
0.33 | 0.35 | 0.37 | 2.89 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.07 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.50 | |
Operating CF per Share |
(1.39) | (1.31) | (1.07) | (0.62) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.01 | |
Capex to Sales |
— | — | — | (0.01) |
Columns are period end dates